Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria

Timothy M. Illidge; Ruth Pettengell; Michael Bayne; Steven Le Gouill; Andrew Bates; John Radford; Jill Tipping; Maureen Zivanovic; Francoise Kraeber-Bodere; Emmanuel Malek; Huglo Damien; Franck Morschhauser

Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria

Timothy M. Illidge, Ruth Pettengell, Michael Bayne, Steven Le Gouill, Andrew Bates, John Radford, Jill Tipping, Maureen Zivanovic, Francoise Kraeber-Bodere, Emmanuel Malek, Huglo Damien, Franck Morschhauser

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Pages (from-to)	49-50
Number of pages	2
Journal	Blood
Volume	118
Issue number	21
Publication status	Published - 2011

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Illidge, T. M., Pettengell, R., Bayne, M., Le Gouill, S., Bates, A., Radford, J., Tipping, J., Zivanovic, M., Kraeber-Bodere, F., Malek, E., Damien, H., & Morschhauser, F. (2011). Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Blood, 118(21), 49-50.

@article{d7c02bfdd1714245af55f34429950583,

title = "Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria",

author = "Illidge, {Timothy M.} and Ruth Pettengell and Michael Bayne and {Le Gouill}, Steven and Andrew Bates and John Radford and Jill Tipping and Maureen Zivanovic and Francoise Kraeber-Bodere and Emmanuel Malek and Huglo Damien and Franck Morschhauser",

year = "2011",

language = "Undefined",

volume = "118",

pages = "49--50",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

number = "21",

}

Illidge, TM, Pettengell, R, Bayne, M, Le Gouill, S, Bates, A, Radford, J, Tipping, J, Zivanovic, M, Kraeber-Bodere, F, Malek, E, Damien, H & Morschhauser, F 2011, 'Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria', Blood, vol. 118, no. 21, pp. 49-50.

Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. / Illidge, Timothy M.; Pettengell, Ruth; Bayne, Michael et al.
In: Blood, Vol. 118, No. 21, 2011, p. 49-50.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria

AU - Illidge, Timothy M.

AU - Pettengell, Ruth

AU - Bayne, Michael

AU - Le Gouill, Steven

AU - Bates, Andrew

AU - Radford, John

AU - Tipping, Jill

AU - Zivanovic, Maureen

AU - Kraeber-Bodere, Francoise

AU - Malek, Emmanuel

AU - Damien, Huglo

AU - Morschhauser, Franck

PY - 2011

Y1 - 2011

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000299597100103&KeyUID=WOS:000299597100103

M3 - Meeting Abstract

SN - 0006-4971

VL - 118

SP - 49

EP - 50

JO - Blood

JF - Blood

IS - 21

ER -

Fractionated (90)y Ibritumomab Tiuxetan (Zevalin (TM)) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria

Research Beacons, Institutes and Platforms

UN SDGs

Other files and links

Cite this